🔴 IRD is trading 5.4% down today following FDA alignment and analyst-driven surge

IRD is trading at $3.83 (5.4% down) in pre-market, giving back a portion of yesterday’s significant gains as the stock enters a consolidation phase.

• The stock recently surged after reaching alignment with the FDA on its pivotal Phase 3 trial for OPGx-LCA5.
• Chardan Capital bolstered investor sentiment by maintaining a Buy rating and a $13 price target for the company.
• Today's pullback is viewed as a normal consolidation following the recent rally, occurring alongside a generally weaker tone in the broader market.